Oxthera News

OxThera appoints new Chief Medical Officer

Press release Stockholm, Sweden, Oct 12, 2017 Dr Bastian Dehmel Appointed CMO of OxThera. Stockholm – 12 October 2017 – […]

OxThera announces new CEO

NEWCEO_ENG

OxThera Raises EUR 32 Million to Complete Development of Oxabact® for Treatment of Primary Hyperoxaluria

November 29, 2016 OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announces today that it has agreed on a EURO 32 […]

Oxabact® granted EMA Orphan Drug Designation for treatment of SBS

OxThera AB announced today that its product Oxabact® has been granted an Orphan Drug Designation in the European Union for […]

OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria

OxThera AB announced today that it has been granted two new US patents and one new Australian patent during the […]

OxThera AB receives SEK 70 million financing to continue its key clinical programs

OxThera AB, a privately-held Stockholm-based biopharmaceutical company, today announced that a syndicate of new investors, led by Kurma Partners, including […]

Georges Gemayel appointed new chairman for OxThera

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that Dr Georges Gemayel has been appointed new chairman of the […]

OxThera initiates clinical trial in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in in Primary Hyperoxaluria. […]

ELIMOX – Partners start drug development in hyperoxaluria

OxThera AB announces today that the FP7-project ELIMOX has started as of 1st of October, 2013. The primary aim of […]

OxThera coordinates FP7 project, ELIMOX – €2.19 million provided for drug development in hyperoxaluria

OxThera AB announces today that it is the coordinator of a new EU-project, ELIMOX, that will run for 2 years […]

EXTERNAL NEWS